Monitor for upcoming clinical catalysts or regulatory updates, as the selling is small but involves key executives. Any further insider sales could amplify bearish sentiment.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $31.01entry
- T+1 · 7mo ago −5.06%α −5.28% · $29.44
- T+5 · 6mo ago −2.90%α −4.63% · $30.11
- T+20 · 6mo ago −3.71%α −8.68% · $29.86
- T+60 · 4mo ago +9.55%α +6.44% · $33.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Pharvaris insiders (CMO, Chief Early Development, Director) sold a combined ~$2.19M in open-market transactions over the past week, representing 0.11% of market cap. Sales are modest relative to company size but involve senior officers, warranting monitoring.
Key Financial Metrics
Key Facts
- Lu Peng (CMO) sold ~$989K across three separate trades.
- Lesage Anne (Chief Early Development) sold ~$223K in two trades.
- Schikan Johannes (Director) sold ~$976K in two trades.
- Total open-market sales: ~$2.19M (0.11% of $2.0B market cap).
- All sales were preceded by option exercises at nominal prices, typical for tax or profit-taking.
Financial Impact
$2.19 million in insider sales over 7 days
Risk Factors
- Continued insider selling may signal low confidence ahead of news.
- No clear catalyst identified, selling may be pre-planned or tax-related.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1778010710838 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers